CERo Therapeutics Doses Second Patient In Phase 1 AML Trial; Reports Early Pharmacokinetic Data With More Than Seven Days Passed Following The Second Patient's Infusion, Monitoring Continues For Key Safety, Tolerability, And Efficacy Endpoints

Author: Benzinga Newsdesk | July 31, 2025 08:11am

Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results

SOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the first cohort of its Phase 1 CER-1236 clinical trial focused on patients with acute myeloid leukemia (AML).  The patient was dosed at the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado, with Yazan Migdady, M.D., an associate member physician at CBCI acting as principal investigator for the study.  With more than seven days passed following the second patient's infusion, monitoring continues for key safety, tolerability, and efficacy endpoints. 

Posted In: CERO